NFKB1 and neoplasm: Sorafenib has been shown to sensitize both human colorectal and oral carcinomas to RT in tumor-bearing mouse models via the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and its downstream effector proteins [17, 18].